Pharma Focus Europe-Newsletter

Pharma Focus Europe-Newsletter

Latest Articles

10 Essential Factors for Selecting a Pharma Publisher in Europe

Selecting the right pharmaceutical publisher plays a vital role for any research going into publication in Europe’s rapidly growing pharma market environment. Based on this study, it is possible to define 10 criteria, which would allow the selection of the most suitable publishers for the given material, such as compliance with legal requirements, the impact factor, language translation, and other aspects of ethical behavior.

10 Essential Factors for Selecting a Pharma Publisher in Europe
Pharma Publisher in Europe

Maximizing ROI: The Secret to Successful Pharma Magazine Advertising

Print media, particularly magazines, continue to offer a valuable way of reaching a well-inspected, informed audience, mostly within the pharma sector. Ultimately, through identifying the audience, telling great stories, applying effective visual design, linking campaign types of both print and online, and employing the big data approach, businesses can achieve the maximum of their return on investment (ROI). Strategic planning leads to excellent and complaint ad campaigns that are most effective and inventive.

Pharma Magazine Advertising
Pharma Magazine Advertising

mRNA Technology: Unlocking New Possibilities In Therapeutics Beyond Vaccines

mRNA technology changes mankind in vaccine development and expands to cancer, genetic disorders, rare diseases, and regenerative medicine. Its possibilities are in cardiology, immunity, and individualized treatment. Issues such as delivery and stability are being addressed, making it possible for a revolution in health care that will address various health problems through the invention of specific therapies.

mRNA Technology
mRNA Technology

Stay updated with the latest articles.


Expert Interviews

The Evolution of Medicine: Exploring Biopharmaceuticals and Biosimilars

Author: Gillian Woollett, and Head of Regulatory Strategy and Policy, Samsung Bioepis

How is innovation driving the development of novel biopharmaceuticals and biosimilars?

Just like with any other industry, biotech relies on new products replacing old—the virtuous cycle. The competition from biosimilars nibbles at the heels of the originators, and they innovate to create novel options as biosimilars replace older biologics with competitive versions that improve access and affordability. Known as the Virtuous Cycle

Biopharmaceuticals and Biosimilars
Biopharmaceuticals and Biosimilars

Supply Chain Planning for Clinical Trials: A Practical Guide

Author: Ryan Mills, Senior Director, Denali Therapeutics

Clinical trials are a critical part of the pharmaceutical development process. These trials cannot proceed without timely and regular receipt of the drugs being tested, which can prove a challenge for drug manufacturers who have not yet established the structures required to produce quality-controlled specimens of the drug at scale. Managing supply chains of pre-production drugs for clinical trials is therefore an essential component of drug development.

Supply Chain Planning for Clinical Trials
Supply Chain Planning for Clinical Trials

Patient-Centric Drug Development: Best Practices and Innovations

Author: Mike Cioffi, Senior Vice President of Clinical Solutions and Strategic Partnerships, WCG, & Anna Worsley, CEO of FABRX-AI and Director of Innovation, FABRX

In recent years, the pharmaceutical industry has increasingly shifted its focus toward patient-centric drug development. This approach aims to integrate the needs, preferences, and experiences of patients into every stage of the drug development lifecycle, from early research to post-market studies. With innovations in technology, regulatory changes, and growing patient advocacy, the industry is exploring how best to deliver therapies that truly align with patient outcomes.

Patient-Centric Drug Development
Patient-Centric Drug Development

Access additional expert interviews.


Industrial Events

Pharmapack Europe

Pharmapack Europe

9th Microbiome Movement Summit Europe

9th Microbiome Movement Summit Europe

World Summit on Pharmaceutics and Drug Designs (WSPDD - 25)

World Summit on Pharmaceutics and Drug Designs (WSPDD - 25)
World Summit on Pharmaceutics and Drug Designs (WSPDD - 25)

Discover additional industrial events.


Industrial Projects

Novo Nordisk Commits 8.5 Billion to Build New Production Facility in Denmark

Novo Nordisk has revealed plans to invest 8.5 billion Danish kroner in the construction of a new production facility in Denmark. This marks the first time in this century that the company has launched a new production site in Denmark.

Ardena Invests €20 million for the Expansion of New Nanomedicine Facility in Netherlands

Ardena has invested €20 million in expanding its nanomedicine manufacturing facility in the Netherlands, achieving full Good Manufacturing Practice (GMP) certification.

Explore more industrial projects.


The Latest Tech Innovations

Gilead's Trodelvy? Receives Breakthrough Therapy Designation for Extensive-Stage Small Cell Lung Cancer

Gilead Sciences has announced that the U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation for Trodelvy? (sacituzumab govitecan-hziy) in the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC)

Tolebrutinib Receives Breakthrough Therapy Designation for Non-Relapsing Secondary Progressive Multiple Sclerosis

The US Food and Drug Administration (FDA) has granted breakthrough therapy designation to tolebrutinib for the treatment of adults with non-relapsing secondary progressive multiple sclerosis (nrSPMS).?

HUTCHMED Announces Breakthrough Therapy Designation for ORPATHYS? and TAGRISSO? Combination for the treatment of EGFR+ NSCLC

HUTCHMED has announced that the Center for Drug Evaluation of China’s National Medical Products Administration (NMPA) has granted breakthrough therapy designation (BTD) to the combination of ORPATHYS? (savolitinib) and TAGRISSO? (osimertinib) for treating patients

More latest tech innovations.


Most Engaging Articles

AI Revolutionizing Drug Discovery: A Pharmacologist's Perspective on the Future of Medicine

Author: Sara M. Elkashef, Ph.D., PharmB, Jubilant Radiopharma

AI is transforming drug discovery, slashing the time and cost to develop new medicines. Recently, cutting-edge AI tools are uncovering drug targets faster, refining potential therapies, and predicting safety with remarkable precision.

AI Revolutionizing Drug Discovery:
AI Revolutionizing Drug Discovery

Orchestrating a Commercially Successful Cell and Gene Therapy: The Role of Technology in Operational Scalability

Author: Akshay Peer, Senior Vice President, Product Development and a Co-founder of TrakCel

In this article, Dr. Akshay Peer, TrakCel’s Senior Vice President Product, explores the evolving challenges of cell and gene therapy orchestration and the critical role of technology in streamlining processes, ensuring patient safety, and promoting standardization.

Cell and Gene Therapy

The Evolution of mRNA Therapeutics: Recent Advances, Challenges, and the Path Forward

Authors: Carl Schoellhammer, Associate Partner, DeciBio, Cassidy Humphreys, Senior Analyst, DeciBio; and Aditi Ghalsasi, Analyst, DeciBio

The mRNA field is maturing beyond pandemic-era vaccines, requiring strategic focus on therapeutic applications beyond infectious diseases. Challenges like improving delivery vehicles and advancing in vivo cell therapies are key to unlocking mRNA’s potential. As the market evolves, finding the right niche are critical for future success

mRNA Therapeutics
mRNA Therapeutics

Discover the most engaging articles


Press Releases

Boehringer provides update on iclepertin Phase III program in schizophrenia

Nusano and Atley Solutions in Collaboration to Accelerate Astatine-211 Development

Lyndra Therapeutics Announces Strategic Clinical Research and Commercial Manufacturing Services Collaboration with Thermo Fisher Scientific for Long-Acting Oral Therapies

Sinaptica Announces Initiation of Co-Development of the SinaptiStim? Precision Neuromodulation System to treat Alzheimer’s Disease; On Track for Pivotal Clinical Trial Initiation in 2025

Discover additional press releases.


?????? ???????????? ???????????????? ?????????? ???????????????? ?????????????????? ??????????????, ???????????? ????????????????, ???????????????? ?????????????? ?????? ???????????? ?????????????? ???? ?????? ???????????????????????????? ???????????? ??????'?? ???????? ????! https://www.pharmafocuseurope.com/magazine

?????????? ?????? ??????????????: https://www.pharmafocuseurope.com

?????????????????? ???????? ???? ?????????????? ?????? ???????? ???????????? ??????????????: https://www.pharmafocuseurope.com/subscribe

?????????????? ?????? ???????????????? ????????????: https://www.pharmafocuseurope.com/archives

???????????????????? ???? ?????????????????????? ???????? ???????????? ?????????? ????????????? ???????????????? ?????? ?????????? ???????? ????????: https://www.pharmafocuseurope.com/advertise

要查看或添加评论,请登录

Pharma Focus Europe的更多文章

社区洞察

其他会员也浏览了